Todas las investigaciones
ReclutamientoFASE2INTERVENCIONISTA

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Crohn's disease is a long-term condition that causes inflammation in the gut, leading to symptoms like belly pain and tiredness. Current treatments don't work for everyone or can stop working over time. This research study is testing new 'targeted therapies' – risankizumab, trosunilimab, lutikizumab, and ABBV-8736 – to see how effective and safe they are for adults with moderate to severe Crohn's disease. About 540 people will take part in this worldwide study. Participants will receive one of the study medicines, given either by injection under the skin or into a vein, and will have regular check-ups to monitor their health and the treatment's effects. The aim is to find better ways to help people living with Crohn's disease.

De un vistazo

Estado
Reclutamiento
Fase
FASE2
Patrocinador
AbbVie
Objetivo de inscripción
590
Inicio
04 Sep 2024
Estimación de finalización
01 Jan 2030

¿De qué trata este estudio?

Crohn's disease is a condition that causes ongoing inflammation in your digestive system, most often in the bowel. This can lead to various uncomfortable symptoms such as tummy pain, diarrhoea, feeling very tired, and losing weight. While there are treatments available for Crohn's, they don't always work for everyone, or their effectiveness might lessen over time. This means doctors are always looking for new and better ways to help people manage their condition.

This study, called a Phase 2 trial, is exploring some newer types of medicines known as 'targeted therapies'. These medicines are designed to specifically block certain parts of the body's immune system that cause inflammation in Crohn's disease. The goal is to see how well these new treatments work in adults who have moderate to severe Crohn's, and to understand any potential side effects they might have.

The specific medicines being tested are risankizumab, trosunilimab, lutikizumab, and ABBV-8736. Participants will be fairly assigned to receive one of these medicines. These treatments are given either as an injection under the skin (like an insulin shot) or as a drip into a vein (like a blood transfusion). Researchers will carefully monitor participants' health throughout the study to learn more about these potential new options for treating Crohn's.

Puntos clave

  • This study is for adults with moderate to severe Crohn's disease whose current treatments aren't fully effective.
  • It's testing four new 'targeted therapy' medicines to see how well they work and if they're safe.
  • Treatments are given either by injection under the skin or by drip into a vein.
  • Participation involves more regular hospital/clinic visits, tests, and keeping a diary.
  • You might get access to new treatments before they are widely available.
  • You can stop participating in the study at any time if you wish.

¿Quién puede ser elegible?

To be considered for this study, you must be an adult aged between 18 and 75 years old and weigh at least 6 stone 4 pounds (40 kg). You need to have a confirmed diagnosis of Crohn's disease for at least three months, with clear signs of inflammation in your bowel as seen during an endoscopy.

Crucially, your current Crohn's treatment must not be working well, or you must have had significant side effects from previous treatments. This study is for people whose Crohn's disease is considered moderate to severe, based on certain medical scores.

There are also some reasons why you wouldn't be able to join. For example, if you've already had bad reactions to similar types of medicine (specifically 'p19 inhibitors', which includes risankizumab), or if you've recently taken part in another trial for a similar new Crohn's medicine. You also can't participate if you have other conditions like ulcerative colitis, certain surgical complications from Crohn's (like an ostomy, a very short bowel, or recent bowel surgery within the last three months).

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Are you an adult aged between 18 and 75?
  2. Do you have a confirmed diagnosis of Crohn's disease for at least three months?
  3. Is your current Crohn's treatment not working well enough, or have you had bad side effects from past treatments?
  4. Do you currently have signs of active inflammation in your bowel?
  5. Have you *not* had severe reactions to similar anti-inflammatory medicines in the past?
  6. Have you *not* had bowel surgery in the last three months, or do you *not* have an ostomy or very short bowel?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you'll be assigned to receive one of the study medicines – risankizumab, trosunilimab, lutikizumab, or ABBV-8736. Depending on the medicine, you'll either have regular injections under your skin that you might learn to do yourself, or you’ll need to come to the hospital or clinic for drips into your vein.

Throughout the study, you'll have more regular visits to the hospital or clinic than you might normally. These visits are important for the research team to closely monitor your health. You'll have medical check-ups, blood tests, and sometimes endoscopies (a procedure to look inside your bowel). The team will also ask you questions about how you're feeling, record any side effects, and you'll complete questionnaires and keep a daily diary to track your symptoms. The total duration of your involvement in the study will be explained to you by the research team.

Riesgos y beneficios potenciales

Taking part in a clinical study can offer the potential benefit of trying a new treatment that might improve your condition when standard options haven't worked well. However, there are also potential risks; the new treatments might have side effects that are not yet fully known, or they might not work for you. The study team will explain all known risks and closely monitor you for any problems. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (255)

  • Digestive Health Specialists /ID# 266216
    Código postal verificado
    Dothan, Estados Unidos· Reclutamiento
  • East View Medical Research /ID# 270377
    Código postal verificado
    Mobile, United States· Reclutamiento
  • Southern California Res. Ctr /ID# 265549
    Código postal verificado
    Coronado, United States· Reclutamiento
  • UC San Diego Health System /ID# 265565
    Código postal verificado
    La Jolla, Estados Unidos· Reclutamiento
  • uc davis medical center - patient support services building /ID# 265554
    Código postal verificado
    Sacramento, United States· Reclutamiento
  • Clinical Applications Laboratories - San Diego - 3rd Avenue /ID# 267391
    Código postal verificado
    San Diego, Estados Unidos· Completado
  • Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 265557
    Código postal verificado
    Colorado Springs, Estados Unidos· Reclutamiento
  • Danbury Hospital, Western Connecticut Health Network /ID# 265556
    Código postal verificado
    Danbury, United States· Reclutamiento
  • Yale University School of Medicine /ID# 266786
    Código postal verificado
    New Haven, Estados Unidos· Reclutamiento
  • Novum Research /ID# 278128
    Código postal verificado
    Clermont, Estados Unidos· Reclutamiento
  • University of Florida College of Medicine /ID# 266930
    Código postal verificado
    Gainesville, Estados Unidos· Reclutamiento
  • Nature Coast Clinical Research - Inverness /ID# 265874
    Código postal verificado
    Inverness, United States· Reclutamiento

Preguntas comunes

What is a 'targeted therapy'?

Targeted therapies are medicines designed to home in on specific parts of the body that cause disease, rather than affecting the whole body. They try to be more precise.

How will I know which treatment I'm getting?

You'll be randomly assigned to one of the study treatments. This is like drawing names from a hat and helps ensure the study results are fair. The team will tell you which one you're on.

Will I have more hospital visits than usual?

Yes, taking part in this study will likely mean more regular visits to the hospital or clinic for check-ups and monitoring compared to your usual care.

¿Puedo abandonar el estudio si cambio de opinión?

Absolutely. You can choose to leave the study at any time, for any reason, and your decision will not affect your ongoing medical care.

¿Qué tipo de pruebas tendré?

You'll have regular medical checks, blood tests, and sometimes endoscopies. You'll also fill out questionnaires and keep a daily diary about your symptoms.

Cómo obtener más información

ABBVIE CALL CENTER

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Study of Targeted Therapies for the Treatment of Adult Parti…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.